The total number of records retrieved from this search are 49. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_397	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result55% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_398	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with SP600125 (100 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result35% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_399	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with 3-MA (5 mM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result44% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_400	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with z-YVAD- fmk (100 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman malignant melanoma cell lines	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration1 MOI	In-vitro result42% cancer cell death at 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces JNK/c-Jun, autophagy and pyroptosis activation	Immunogenic effectICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes	Clinical trialNA	PMID26602205
IDOV_619	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result77% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_620	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result77% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_621	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result52% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_622	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result48% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_623	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_624	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result60% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_625	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_626	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result48% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_627	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result40% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_628	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result38% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_679	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result120% cancer cell viability (calculated as relative to mock-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_680	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result105% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_681	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_682	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result70% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_683	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_1437	Virus nameAdenovirus	Virus strainZD-55-IL-18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-18 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro resultCell survival observerd	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19498459
IDOV_1438	Virus nameAdenovirus	Virus strainZD-55-IL-18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-18 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultCell survival observerd	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19498459
IDOV_1439	Virus nameAdenovirus	Virus strainZD-55-IL-18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-18 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultCell survival observerd	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19498459
IDOV_1440	Virus nameAdenovirus	Virus strainZD-55-IL-18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-18 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19498459
IDOV_1441	Virus nameAdenovirus	Virus strainZD-55-IL-18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-18 gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19498459
IDOV_4294	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman skin malignant melanoma	Cell lineA375	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result47.3 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4379	Virus nameNewcastle disease virus	Virus strainMTH-68/H	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman primary melanoma cell line	Cell lineA375	Concentration of cell line250 cells per well	In-vitro toxicityNA	AssayLuciferase based ATP assay	In-vitro virus concentration0.948 MOI	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedER stress and apoptotic pathway	Immunogenic effectIFN production increased	Clinical trialNA	PMID26408702
IDOV_4392	Virus nameNewcastle disease virus	Virus strainMTH-68/H	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman primary melanoma cell line	Cell lineA375	Concentration of cell line250 cells per well	In-vitro toxicityNA	AssayLuciferase based ATP assay	In-vitro virus concentration4.43 MOI	In-vitro result80% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedER stress and apoptotic pathway	Immunogenic effectIFN production increased	Clinical trialNA	PMID26408702
IDOV_5312	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability on day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5313	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell viability on day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5314	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result87% cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5315	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result80% cell viability on day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5316	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell viability on day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5317	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result82% cell viability on day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5318	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result78% cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5319	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result65% cell viability on day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5320	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result82% cell viability on day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5321	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result78% cell viability on day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5322	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result62% cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5323	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result42% cell viability on day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5324	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result70% cell viability on day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5325	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result58% cell viability on day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5326	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result50% cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5327	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result30% cell viability on day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5328	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with DTIC 200 microgram per ml	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result65% cell viability on day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5329	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with DTIC 200 microgram per ml	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result52% cell viability on day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5330	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with DTIC 200 microgram per ml	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result38% cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5331	Virus nameAdenovirus	Virus strainZD55-IL18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationvirus having insertion of IL18 gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with DTIC 200 microgram per ml	Immune gene insertion in viral genomeVirus expressing IL18 gene	Source of cell lineNA	Origin of cell lineHuman skin melanoma cell line	Cell lineA375	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability on day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID27895465
IDOV_5602	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration37 pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5821	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman melanoma cell line	Cell lineA375	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration37 pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578